Alagille syndrome
Drug research and approvals for alagille syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 10 studies of alagille syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 10
- Trials authorized in Canada: 8
- FDA orphan approvals: 3
- EU medicines: 2
Recruiting Now
Newest start dates first, of 10 recruiting on ClinicalTrials.gov ↗- Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille…NCT07335523 · Not reported · Digestive Care, Inc. · starts Aug 3, 2026
- A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving…NCT07585097 · Not reported · Ipsen · starts Jul 10, 2026
- Pediatric Evaluation and Registry for Liver Cholestasis in CanadaNCT07411716 · Not reported · Children's Hospital of Eastern Ontario · starts Apr 21, 2026
- Dental Dyschromia and Quality of Life in Early Prolonged HyperbilirubinemiaNCT06506734 · Not reported · University Hospital, Toulouse · starts Apr 7, 2026
- A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial…NCT07293897 · Not reported · Takeda · starts Jan 13, 2026
- Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome…NCT07290257 · Phase 4 · Mirum Pharmaceuticals, Inc. · starts Sep 25, 2025
- A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome…NCT06850038 · Not reported · Ipsen · starts Apr 22, 2025
- Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)NCT06193928 · Not reported · Mirum Pharmaceuticals, Inc. · starts Sep 21, 2023
- Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)NCT06767605 · Not reported · Asociación Española para el Estudio del Hígado · starts Jan 1, 2016
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · Not reported · Sanford Health · starts Jul 1, 2010
Trials Authorized in Canada
Newest first; search them all in Canada trials| Aug 26, 2021 | An open label study to evaluate the long-term safety and efficacy of odevixibat (a4250) in patients with alagille syndromeODEVIXIBAT (A4250) | ALBIREO AB | Closed |
| Dec 22, 2020 | A phase 3 double-blind, randomized, placebo-controlled study of the safety and efficacy of odevixibat (a4250) in patients with alagille syndrome (assert)ODEVIXIBAT (A4250) | ALBIREO AB | Closed |
| Feb 14, 2020 | A long-term safety study of maralixibat, an apical sodium dependent bile acid transporter inhibitor (asbti), in the treatment of cholestatic liver disease in…MARALIXIBAT (LUM001, SHP625) | Mirum Pharmaceuticals | Closed |
| Jun 5, 2014 | A multicenter extension study to evaluate the long-term safety and durability of the therapeutic effect of lum001, an apical sodium-dependent bile acid…MARALIXIBAT (LUM001) | Mirum Pharmaceuticals | Ongoing |
| Apr 23, 2014 | Iconic study long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period of lum001, an apical sodium-dependent bile…MARALIXIBAT (LUM001) | LUMENA PHARMACEUTICALS INC | Closed |
| Feb 6, 2014 | A multicentre extension study to evaluate the long-term safety and durability of the therapeutic effect of lum001, an apical sodium-dependent bile acid…LUM001 | LUMENA PHARMACEUTICALS INC | Closed |
| Feb 6, 2014 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lum001, an apical sodium-dependent bile acid transporter inhibitor…LUM001 | LUMENA PHARMACEUTICALS INC | Closed |
| Feb 6, 2014 | The evaluation of the intestinal bile acid transport (ibat) inhibitor lum001 in the reduction of pruritus in alagille syndrome, a cholestatic liver diseaseMARALIXIBAT (LUM001) | LUMENA PHARMACEUTICALS INC | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Jun 13, 2023 | Bylvaytreatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS) | Ipsen Biopharmaceuticals, Inc. | Approved |
| Mar 13, 2023 | Livmarlitreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older | Mirum Pharmaceuticals, Inc. | Approved |
| Sep 29, 2021 | LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older | Mirum Pharmaceuticals, Inc. | Approved |
| Oct 24, 2024 | 27mer antisense oligonucleotide with methoxyethyl,…treatment of Alagille syndrome | Arnatar Therapeutics, Inc. | Designated |
| Sep 3, 2004 | Buffered Ursodeoxycholic AcidTreatment of pruritus in patients with Alagille Syndrome | Digestive Care, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Sep 19, 2024 | Kayfandaodevixibat | Ipsen Pharma | EMA ↗ |
| Dec 9, 2022 | Livmarlimaralixibat chloride · orphan | Mirum Pharmaceuticals International B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA